CJC-1295 research at getgoodpeptides
An albumin attachment gave this GHRH analog an unusually long stay in the blood. I admire the engineering and still want a useful outcome to follow it.
Albumin binding: DAC versus no-DAC
CJC-1295 begins with the first 29 residues of human growth-hormone-releasing factor and adds four stabilizing substitutions. Its DAC form adds an attachment that binds covalently to albumin, a circulating blood protein. That attachment extends exposure to days. The short-acting no-DAC form, often called Modified GRF 1-29, lacks the albumin-binding chemistry. The GHRH-analogue review places these designs alongside sermorelin and tesamorelin.
Confusing the forms spoils the comparison before it starts. I credit a duration finding only to the form actually studied; a short-acting analog cannot inherit the DAC results through a shared name.
CJC-1295 mechanism of action
At the pituitary GHRH receptor, CJC-1295 activates signaling that stimulates synthesis and release of GH, followed downstream by IGF-1. The albumin attachment changes how long the signal can persist. It does not replace the receptor mechanism with a new one.
In the 2006 study in healthy adults aged 21–61, mean GH increased 2- to 10-fold for 6 days or more, and IGF-1 increased 1.5- to 3-fold for 9–11 days after a single research dose. Estimated half-life was 5.8–8.1 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The distinction between single and multiple exposures matters here.
Those sustained measurements are impressive to me, while their clinical significance remains open. The study measured hormone responses; it leaves lasting changes in strength, sleep and everyday function to other experiments.
Natural pulses and serum proteins
A separate study in healthy men aged 20–40 found that pulsatile GH secretion persisted during sustained stimulation. Frequency and magnitude of pulses were unaltered, even as trough GH rose approximately 7.5-fold. That makes the physiology subtler than a hormone simply being switched on continuously.
The 2009 serum-protein study in 11 healthy young men took another direction. Apolipoprotein A1 and a transthyretin isoform decreased; albumin fragments and immunoglobulin species increased, with signals correlating with IGF-1. These were candidate biomarkers of activation. The protein changes leave me curious about their relationship to a useful clinical outcome.
Development and safety
CJC-1295 has no drug approval, and its original development programme was halted. A reported death from that era has been discussed publicly, but the record does not establish that CJC-1295 caused it. On FDA’s page current as of April 22, 2026, its nomination is listed as withdrawn, with safety concerns still recorded, including immunogenicity: the possibility of an immune response to the peptide. Withdrawal confers neither compounding permission nor Category 1 status.
Early human studies reported mostly mild reactions, including local irritation, flushing and headache. They do not resolve long-term safety. Sustained GH/IGF-1 exposure raises concerns about fluid retention, glucose regulation and growth signaling; the cancer concern is mechanistic, not a demonstrated CJC-1295 cancer outcome. WADA prohibits CJC-1295 at all times under S2.
Community reports and combinations
Sleep, training recovery and gradual fat loss feature in community accounts, as do puffiness, tingling, headaches and fatigue. These accounts are anecdotal, not clinical evidence. Mixed reports of more energy and more tiredness are a useful warning against expecting one predictable experience.
The proposed pairing with ipamorelin combines GHRH-receptor and ghrelin-receptor stimulation. A review describes combination findings in a mouse muscle-loss model; no controlled human trial establishes the combination’s benefit. The albumin chemistry earns my enthusiasm; an untested human pairing deserves more skepticism. The comparison sets that evidence beside the other compounds.